WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
The company does not expect the outcome of this inspection to impact its plans
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
This facility plays an important role in Granules’ global manufacturing and supply network
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
The Establishment Inspection Report came following closure of a product- specific pre-approval inspection from March 2 to March 7, 2026
For the full year, standalone gross revenue crossed Rs. 1,700 crore
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
Subscribe To Our Newsletter & Stay Updated
